Neoadjuvant Listeria or Daratumumab in Prostate Cancer
Status:
Withdrawn
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn about biomarker changes in patients who
have primary prostate cancer after receiving Darzalex (daratumumab) and then have a
prostatectomy (the surgical removal of the prostate) as part of their standard care.
Biomarkers are found in the blood/tissue and may be related to your reaction to the study
drug.